Story perspectives

Anito-cel Shows Promising Results for Multiple Myeloma Treatment

12/8/2025

Summary

Story summary

Gilead Sciences focuses on its CAR-T therapy, anito-cel, for multiple myeloma as sales decline.
Data at the American Society of Hematology meeting show 96% responded, 74% in complete remission.
Anito-cel uses a novel synthetic protein with a favorable safety profile and low-grade side effects.
Kite Pharma's leader expresses confidence in anito-cel as an outpatient therapy.
Analysts say the results could drive physician enthusiasm for the drug in the U.S.

1 of 1

Story summary

Gilead Sciences focuses on its CAR-T therapy, anito-cel, for multiple myeloma as sales decline.
Data at the American Society of Hematology meeting show 96% responded, 74% in complete remission.
Anito-cel uses a novel synthetic protein with a favorable safety profile and low-grade side effects.
Kite Pharma's leader expresses confidence in anito-cel as an outpatient therapy.
Analysts say the results could drive physician enthusiasm for the drug in the U.S.